Belimumab

Drug Profile

Belimumab

Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LymphoStat-B

Latest Information Update: 23 May 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology; Human Genome Sciences
  • Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; Hospital for Special Surgery; Human Genome Sciences; North Shore-Long Island Jewish Health System; University of Pennsylvania
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Systemic lupus erythematosus
  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis
  • Phase II/III Myositis
  • Phase II Membranous glomerulonephritis; Myasthenia gravis; Renal transplant rejection; Sjogren's syndrome; Systemic scleroderma
  • No development reported Waldenstrom's macroglobulinaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 08 May 2017 The Scottish Medicines Consortium accepts belimumab for the treatment of autoantibody-positive Systemic lupus erythematosus
  • 27 Apr 2017 GlaxoSmithKline initiates an expanded access for Systemic lupus erythematosus in USA before April 2017 (NCT03125486)
  • 01 Feb 2017 GlaxoSmithKline completes a phase III trial in Vasculitis in USA, Canada, Mexico, Peru, Australia, United Kingdom, Ireland, Belgium, Czech Republic, Germany, Hungary, Italy, Poland, Romania, Sweden, Spain, Switzerland, Norway and Russia (NCT01663623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top